found that when combined with exosome inhibitor GW4869 or knockout Rab27a and PD-L1 antibody, the therapeutic effect of anti-PD-L1 antibody can be enhanced in a PD-L1-dependent manner and much stronger tumor suppression (26). The gene discussed is CD274; the disease is neoplasm.